Bristol-Myers Squibb (BRM) Price & Analysis

Compare

19 Followers

BRM Stock Chart & Stats

€51.35

-€0.23(-0.42%)

At close: Jan 08 4:00 PM EST

€51.35

-€0.23(-0.42%)

Day’s Range― - ―

52-Week Range€36.60 - €58.20

Previous CloseN/A

Volume2.10K

Average Volume (3M)2.48K

Market Cap

$103.45B

Enterprise Value€160.46B

Total Cash (Recent Filing)$10.67B

Total Debt (Recent Filing)$47.14B

Price to Earnings (P/E)16.4

Beta0.48

Next Earnings

Apr 30, 2026

EPS Estimate

1.22

Next Dividend Ex-DateN/A

Dividend Yield5.01%

Share Statistics

EPS (TTM)1.07

Shares Outstanding2,036,473,800

10 Day Avg. Volume1,969

30 Day Avg. Volume2,483

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)5.96

Price to Sales (P/S)2.28

P/FCF Ratio8.57

Enterprise Value/Market Cap1.55

Enterprise Value/Revenue3.33

Enterprise Value/Gross Profit4.92

Enterprise Value/Ebitda11.03

Forecast

1Y Price Target

$52.05

Price Target Upside1.37% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Growth Portfolio Commercial MomentumStronger-than-expected sales for growth-stage medicines such as Reblozyl, Breyanzi, and Camzyos helped drive revenue and earnings beats, supporting confidence in the company's ability to offset declines in legacy products.

Milvexian Program DeriskingFavorable late-stage results from a competitor's anticoagulant provide a positive clinical readthrough that reduces uncertainty around milvexian's prospects and increases confidence ahead of its pivotal data.

Pricing And ReimbursementNew U.S. pricing rules and a one-time pricing adjustment reduced rebate and penalty liabilities for Eliquis, improving revenue predictability and providing additional cash flow to support growth-stage launches.

Bears Say

Accelerated Approval Conversion RiskReliance on minimal residual disease for accelerated approval means conversion to full approval will require confirmatory progression-free survival or overall survival benefits, creating regulatory uncertainty until those outcomes are achieved.

Concentrated Pipeline Readout RiskA concentration of important registrational readouts across multiple late-stage programs increases clinical and regulatory risk and could cause pronounced swings in investor expectations if key results disappoint.

Iberdomide Safety And TolerabilitySelection of a low iberdomide dose and prior observations of neutropenia raise safety and tolerability concerns that could limit dosing flexibility and commercial adoption.

Bristol-Myers Squibb News

Barclays Bank (BCS) Names Four Pharma Stocks to Buy Now

Eli Lilly is the firm’s top pick among medicine companies. ...

3d ago

BCS

BMY

Bristol Myers initiated with an Overweight at Barclays

Barclays initiated coverage of Bristol Myers (BMY) with an Overweight rating and $75 price target The company is...

3d ago

BMY

FDA to begin requiring on clinical trial

The New England Journal of Medicine reports: “Sounding Board announces a new FDA policy that the default requirement...

4d ago

AZN

BMY

FDA to begin requiring one clinical trial in drug approvals

The New England Journal of Medicine reports: “Sounding Board announces a new FDA policy that the default requirement...

4d ago

AZN

BMY

Bristol Myers says FDA accepts NDA for iberdomide

Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted a New Drug Application for iberdomide combined...

6d ago

BMY

Bristol Myers’ treatment of follicular lymphoma granted FDA orphan designation

Bristol Myers (BMY)’ treatment of follicular lymphoma was granted FDA orphan designation, according to a post on the...

9d ago

BMY

Bristol Myers price target raised to $40 from $37 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37...

17d ago

BMY

Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

17d ago

AZN

Bristol Myers price target raised to $68 from $64 at BofA

BofA raised the firm’s price target on Bristol Myers (BMY) to $68 from $64 and keeps a Buy...

17d ago

BMY

Bristol Myers price target raised to $72 from $62 at Guggenheim

Guggenheim raised the firm’s price target on Bristol Myers (BMY) to $72 from $62 and keeps a Buy...

17d ago

BMY

Bristol Myers price target raised to $64 from $60 at Citi

Citi raised the firm’s price target on Bristol Myers (BMY) to $64 from $60 and keeps a Neutral...

17d ago

BMY

BMY’s Mavacamten Safety Extension Wraps Up, Sharpening the Long-Term Outlook in Hypertrophic Cardiomyopathy

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has reported a...

3d ago

BMY

Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating today....

6d ago

BMY

BMY-Backed Milvexian Stroke Trial Moves Forward, Keeping Upside Optionality Alive

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The LIBREXIA-STROKE study tests milvexian in...

10d ago

BMY

BRM FAQ

What was Bristol-Myers Squibb’s price range in the past 12 months?

Bristol-Myers Squibb lowest stock price was €36.60 and its highest was €58.20 in the past 12 months.

What is Bristol-Myers Squibb’s market cap?

Bristol-Myers Squibb’s market cap is $103.45B.

When is Bristol-Myers Squibb’s upcoming earnings report date?

Bristol-Myers Squibb’s upcoming earnings report date is Apr 30, 2026 which is in 66 days.

How were Bristol-Myers Squibb’s earnings last quarter?

Bristol-Myers Squibb released its earnings results on Feb 05, 2026. The company reported €1.065 earnings per share for the quarter, beating the consensus estimate of €1.037 by €0.029.

Is Bristol-Myers Squibb overvalued?

According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bristol-Myers Squibb pay dividends?

Bristol-Myers Squibb pays a Quarterly dividend of €0.528 which represents an annual dividend yield of 5.01%. See more information on Bristol-Myers Squibb dividends here

What is Bristol-Myers Squibb’s EPS estimate?

Bristol-Myers Squibb’s EPS estimate is 1.22.

How many shares outstanding does Bristol-Myers Squibb have?

Bristol-Myers Squibb has 2,036,473,800 shares outstanding.

What happened to Bristol-Myers Squibb’s price movement after its last earnings report?

Bristol-Myers Squibb reported an EPS of €1.065 in its last earnings report, beating expectations of €1.037. Following the earnings report the stock price went up 4.011%.

Which hedge fund is a major shareholder of Bristol-Myers Squibb?

Currently, no hedge funds are holding shares in DE:BRM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bristol-Myers Squibb Stock Smart Score

Outperform

Fundamentals

Return on Equity

40.53%

Trailing 12-Months

Asset Growth

-2.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb (BRM) Earnings & Revenues

Historic Earnings Reports

BRM Company Deck

BRM Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all DE:BRM earnings summaries

BRM Revenue Breakdown

54.80% Growth Portfolio

45.20% Legacy Portfolio

BRM Stock 12 Month Forecast

Average Price Target

€52.05

▲(1.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","40":"€40","48":"€48","56":"€56","64":"€64"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63.4177605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€63.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.0532978184,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€52.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.8228056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,40,48,56,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,48.28136619230769,49.542732384615384,50.80409857692308,52.06546476923077,53.32683096153846,54.58819715384615,55.84956334615384,57.11092953846154,58.37229573076923,59.63366192307692,60.89502811538462,62.15639430769231,{"y":63.4177605,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,47.40717675526154,47.79435351052308,48.181530265784616,48.56870702104616,48.955883776307694,49.34306053156923,49.73023728683077,50.11741404209231,50.50459079735384,50.891767552615384,51.27894430787692,51.66612106313846,{"y":52.0532978184,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.02,46.004831200000005,44.9896624,43.9744936,42.959324800000005,41.94415600000001,40.9289872,39.913818400000004,38.8986496,37.8834808,36.868312,35.853143200000005,34.8379744,{"y":33.8228056,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.695,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.778,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.238,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.834,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.404,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.489,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.881,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >